Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to ...
Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.
AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.
AbbVie invests $380m in North Chicago for API manufacturing, creating 300 jobs, boosting US R&D, and expanding domestic ...
As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...
The partnership combines Ginkgo's AI/ML and enzyme engineering expertise with Prozomix's wealth of enzyme sequence data to create best-in-class enzymes for API manufacturing This agreement also marks ...
Eli Lilly and Company has announced plans to invest $6.5bn in an active pharmaceutical ingredients (API) manufacturing facility at Generation Park in Houston, in the US state of Texas. The new ...